IntoCell, Inc.

IntoCell develops protein-drug conjugates for the treatment of cancer. It develops antibody drug conjugates (ADC), fusion albumin drug conjugates, and triple conjugates. It also develops B7-H3 ADC, which is in preclinical Phase for the treatment of solid cancers, as well as HER3 ADC, 5T4 ADC, and PSMA ADC for solid cancers. Additionally, it develops Ortho-Hydroxy Protected Aryl Sulfate (OHPAS), a novel self-immolative group that designs to incorporate various functional groups for linking targeting moieties

OHPASM Linker-toxin Library, an optimized linker-toxin library for fast delivery of a pre-clinical candidate in novel ADC programs. Founded in 2015, the company is based in Daejeon, South Korea.